{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:46:56Z","timestamp":1792806416379,"version":"4.5.0"},"reference-count":9,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Trastuzumab, a humanized monoclonal antibody, significantly improves outcomes in HER2-neu positive breast cancer. The incidence of cardiotoxicity with trastuzumab is approximately 8 to 10%. This study was designed to analyze the incidence and risk factors associated with trastuzumab-related cardiotoxicity in real-world settings. This was a single institutional retrospective analysis of the incidence of trastuzumab-related cardiotoxicity in nonmetastatic HER2-positive, invasive breast cancer from January 2013 to December 2018. Trastuzumab-related cardiotoxicity was defined as symptomatic heart failure or asymptomatic decline in left ventricular ejection fraction (LVEF) by more than or equal to 10% or LVEF less than 50%. Risk factors analyzed were higher body mass index (\u226530\u2009kg\/m2), history of diabetes, hypertension, cardiac disease, left-sided radiotherapy (RT), and prior exposure to anthracyclines. Out of the 246 patients diagnosed with early stage HER2-positive breast cancer, 117 (47.5%) received trastuzumab and constituted the study population. Trastuzumab-related cardiotoxicity was seen in a total of 16 (13.6%) patients. Eleven (9.4%) patients had an asymptomatic decline, while symptomatic LV dysfunction was seen in five (4.2%) patients. The median baseline ejection fraction was 65% (range, 56\u201372). The median time to development of cardiotoxicity was 18.5 weeks (range, 3\u201352) and the median trastuzumab cycle for cardiotoxicity was 6 (range, 2\u201316). Ten (62.5%) patients were rechallenged with trastuzumab following which one patient developed an asymptomatic decline in ejection fraction and one patient developed symptomatic heart failure. Cardiac-related mortality was seen in one (0.85%) patient. Left-sided RT to chest (p\u2009=\u20090.012) and presence of more than or equal to two risk factors (p\u2009=\u20090.01) had significant impact on incidence of cardiotoxicity. Approximately 14% developed trastuzumab-related cardiotoxicity that was slightly higher compared with that seen in clinical trials. Left-sided RT to chest and presence of two or more risk factors had significant impact on development of cardiotoxicity.<\/jats:p>","DOI":"10.1055\/s-0043-1768039","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:21:10Z","timestamp":1695842470000},"page":"233-237","source":"Crossref","is-referenced-by-count":5,"title":["Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario"],"prefix":"10.25259","volume":"12","author":[{"given":"Sarita","family":"Shrivastva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stalin Chowdary","family":"Bala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-6901","authenticated-orcid":false,"given":"Rachana","family":"Chennamaneni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Lakshmi","family":"Konatam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswara Rao","family":"Pydi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuruva Siva","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadashivudu","family":"Gundeti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4161\/onci.20447","article-title":"Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells","volume":"1","author":"T Kute","year":"2012","journal-title":"OncoImmunology"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"N Mohan","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"ref3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"M J Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","article-title":"Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study","volume":"117","author":"D Wadhwa","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12032-017-1018-y","article-title":"Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single \u201creal-world\u201d setting","volume":"34","author":"G H Tang","year":"2017","journal-title":"Med Oncol"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"D Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"D P Leong","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"08","key":"ref9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"E A Perez","year":"2008","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canrad.2014.01.001","article-title":"Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy","volume":"18","author":"L Cao","year":"2014","journal-title":"Cancer Radiother"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1768039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:46Z","timestamp":1781176366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/trastuzumab-related-cardiotoxicity-in-adjuvant-setting-a-real-world-scenario\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":9,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1768039","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}